The Wall Street Journal129d agobullish
Roche Lung-Cancer Drug Candidate Beats Existing Therapies in Late-Stage TrialNotícias
Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.
105last 24h
3126last 7d
510● bullish (7d)
311● bearish (7d)
227publishers
The Wall Street Journal129d agobullish
Roche Lung-Cancer Drug Candidate Beats Existing Therapies in Late-Stage TrialThe Wall Street Journal135d agoneutral
European Regulator Calls for Amgen’s Tavneos to Have Authorization RevokedThe Wall Street Journal165d agoneutral
A New, Powerful Cholesterol-Lowering Drug Is on the HorizonThe Wall Street Journal171d agoneutral
Amgen Drug Gets New Warnings in Japan After Patient DeathsSimply Wall St.177d agoneutral
How The Amgen (AMGN) Investment Story Is Shifting With New Guidance And Pipeline UpdatesInvestor's Business Daily187d agoneutral
How This Amgen Rival, Up 33%, Plans To Shake Its Grip In Thyroid Eye Disease24/7 Wall St.188d agoneutral
Guggenheim Trims Amgen Price Target to $340: Is the Biotech Giant Losing Its Edge?